retatrutide phase 2 trial results weight loss Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 conducted in the USA 💉 A triple-action once-weekly injection

Description

There are no separate per-visit fees

A.GirardiA

Prescribers can recommend customized dose intervals, split doses, or adjusted concentrations if a patient experiences side effects or plateaus in weight loss response

Through detailed molecular analysis, LC-MS enables scientists to detect sequence variants, degradation products, and process-related impurities that may arise during peptide synthesis or formulation

Why it matters: Despite consumer interest in lower-cost compounded GLP-1s, Hims is phasing out the business, which now faces risk of obsolescence, CFO Yemi Okupe said on the earnings call